Behind the Study: PRAME Associated with Increased Metastatic Risk
June 7, 2021
Dr. Matthew G. Field discusses his 2016 study published by Oncotarget, entitled, “Epigenetic reprogramming and aberrant expression of PRAME are associated with increased metastatic risk in Class 1 and Class 2 uveal melanomas.” continue reading »